ZynexZYXI
About: Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
Employees: 1,000
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
4% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 25
5.05% less ownership
Funds ownership: 25.12% [Q4 2024] → 20.07% (-5.05%) [Q1 2025]
10% less funds holding
Funds holding: 96 [Q4 2024] → 86 (-10) [Q1 2025]
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
62% less call options, than puts
Call options by funds: $15K | Put options by funds: $39K
78% less capital invested
Capital invested by funds: $64.1M [Q4 2024] → $14.1M (-$50M) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
RBC Capital Shagun Singh | 90%upside $4 | Sector Perform Maintained | 30 Apr 2025 |
HC Wainwright & Co. Yi Chen | 281%upside $8 | Buy Maintained | 30 Apr 2025 |
Financial journalist opinion
Based on 41 articles about ZYXI published over the past 30 days









